A 39-year-old man presented with cough, chest discomfort, and weight loss. On the basis of the patient history and laboratory findings, he was diagnosed with the hypereosinophilic syndrome. Transthoracic echocardiography revealed a large thrombus in the left ventricle. Medical treatment with anticoagulation and immunosuppression was commenced immediately. Fourteen days after the initial diagnosis, the patient presented with acute pain in his right leg. Computed tomographic angiogram showed embolic occlusion of the infrarenal abdominal aorta and bilateral iliac (including common, external, and internal iliac) arteries. Emergent thromboembolectomy and left ventricular thrombectomy were performed. The postoperative course was uneventful, and the patient has undergone follow-up for 2 months without any evidence of recurrence of thromboembolism. 
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− 479 − Further, the left ventricular thrombus was more solid than the usual fresh thrombus, and the margin between the thrombus and the endocardium was unclear. All visible thrombus was removed with care so as to not injure the endocardium and the myocardium (Fig. 3A) . Although there was a moderate degree of mitral regurgitation at the preoperative echocardiography, intraoperative findings after thrombectomy revealed an intact mitral annulus without abnormal thickening or elongation of the subvalvular apparatus. The saline test also demonstrated only a minimal leakage. Due to these findings and the concern of a recurrent thrombosis around the prosthetic mitral ring, the mitral valve procedure was not performed.
Cardiopulmonary bypass and aortic cross-clamp times were 68 and 32 minutes, respectively. The operation and the postoperative course were uneventful. The patient was extubated 12 hours after the surgery. A combination therapy of hydroxyurea and imatinib was sustained with the tapering of mPD.
Postoperative CTA performed at postoperative day 2 and echocardiography at postoperative day 15 revealed the disappearance of the abdominal and iliac thromboembolism, and left ventricular thrombus, respectively (Fig. 3B, C) . Mitral regurgitation was also improved to less than a mild degree.
Although we performed a pathologic evaluation of the re- Recently, HES has been considered a myeloproliferative disorder, and an evaluation of the genetic mutation is helpful in selecting a treatment regimen [1] . Cardiac involvement of the HES occurs in more than 50% of the patients with various symptoms, such as dyspnea, chest pain, cardiac murmur, and congestive heart failure [3, 4] . Cardiac involvement of HES is classified in three stages: first is the acute necrotic stage, which is characterized by myocardial necrosis with eosinophilic infiltration into the myocardium. Second is the thrombotic stage, which is triggered by the damaged endocardial surface in any cardiac chamber. The last is the fibrotic stage, which occurs with the replacement of thrombus by endomyocardial fibrosis. As a result, restrictive cardiomyopathy and valvular incompetence, such as mitral regurgitation, could occur [1, 5] . Medical treatment of the HES included anticoagulation and immunosuppressive therapy. When the PDGFRA or various PDGFRB fusion genes are identified, imatinib shows good long-term efficacy with a low incidence of grade III/IV toxicity [1] . In addition, myeloid neoplasms associated with the rearrangement of PDGFRB are responsive to imatinib [6] . Therefore, in the present case, the patient harbored PDGFRB/5q32 gene re-arrangement and imatinib was included in the treatment regimen.
Most reported cases of HES with cardiac involvement underwent cardiac surgery due to restrictive cardiomyopathy and mitral regurgitation at the chronic stage [7, 8] . In addition, although previous reports presented HES patients with the left ventricular thrombus, data preferring medical or surgical treatment are lacking [4] . The patient in the present study suffered from non-specific symptoms, such as cough, weight loss, chest discomfort, and dyspnea. Echocardiography was Although there has been no guideline for anticoagulation in such patients, we planned to continue oral anticoagulation until 6 months after the initial treatment, which might be suffi-
